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Abstract The high mortality rate of diseases of the aorta
has its foundation in imaging methods that define anatomy
and disease burden but less so upon the diagnosis of
asymptomatic conditions, rate of aneurysm expansion, or
prediction of rupture. However, anatomical features can
now be co-localized with molecular and physiological
activity. The advancement of nanoparticles based upon iron
oxide will also serve to bring a trio of magnetic,
radionuclide, and optical imaging modalities together. The
combinations of these technologies are still at the preclin-
ical refinement stage but already enzyme-activatable probes
have been used to interrogate different stages of aneurysmal
disease. Like many disease areas where in vivo optical
imaging may play a major role in the future, unravelling
and management of aortic aneurysmal disease will progress
through better understanding of its pathophysiology. This
will translate into new clinical applications led by target-
specific probes and the use of nanoparticle technology.
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Introduction
Aortic disease is a complex, but potentially deadly disorder,
where misdiagnosis is often high. The ability to be able to
discern the specific ailment means the difference between
surgical intervention and drug therapy. In particular, many
physicians have difficulty distinguishing between an aortic
aneurysm and an aortic dissection, which are indeed the
two most common diseases of the aorta. New molecular
imaging techniques may provide a path to earlier detection
of symptoms by targeting specific inflammation targets.
Diseased aortic tissue is characterized by chronic
inflammation of the aortic wall, degeneration of the smooth
muscle cells in the aortic wall, followed by destruction of
connective tissue. The diseased tissue is weak and is devoid
of sufficient elasticity to stretch and contract optimally. The
first indication of this abnormality may be a localized
enlargement in the area of weakness and is referred to as an
aneurysm. Aortic tissue may also tear, even if the aorta is
not enlarged, in a process known as dissection. Tearing of the
inner layer of the vessel wall allows blood to leak into the
middle layer of the aorta, separating the inner and outer layers.
The causes and risk factors for aortic aneurysms also fall
into a number of different categories. Bicuspid aortic
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disease is a manifestation usually attributed as being
congenital. Inherited conditions such as Marfan’s syndrome
and Ehlers-Danlos syndrome [1] demonstrate weakening of
the walls of the major arteries, including the aorta. There
are also other connective tissue disorders such as Marfa-
noid, which can lead to the same symptoms. Atherosclero-
sis changes the lining of the artery wall that may affect
oxygen and nutrient flow to the aortic wall tissues. Thus,
the result of tissue hardening followed by breakdown may
lead to the development of an aneurysm. Miscellaneous
infectious and inflammatory conditions such as Takayasu
disease [2], though rare and of unknown etiology, can
impact upon aortic disease development. Physical trauma,
such as an intense blow to the chest or abdomen, can also
directly damage the aorta.
This review will focus upon the inflammatory aspects
that underpin the pathological processes during develop-
ment of an aneurysm. The recent developments in the use
of molecular imaging will be explored, and especially the
diagnostic potential of optical imaging techniques, will be
discussed.
Aortic Aneurysms and Inflammation
Imaging of aneurysms has tended historically to quantify
the size of an aneurysm based upon surveillance of
anatomical features. However, the pathophysiology of
aneurysm formation is associated with an inflammatory
cell infiltrate and enzymatic degradation of the vessel wall
[3]. Biological markers of inflammation have been associ-
ated with risk of aortic rupture [4]. Thus, targeting vascular
inflammation through molecular imaging techniques might
provide valuable functional information about aneurysms.
Recent work has also shown that uptake of magnetic
nanoparticles at the luminal surface of patients with high-
risk aortic aneurysms correlated with thrombus leukocyte
infiltration levels and proteolytic enzyme activity [5]. In the
abdominal aorta, the destruction of elastic laminae is
characteristic of aneurysm formation. This elastinolysis
correlates with overexpression of various elastolytic
enzymes, including matrix metalloproteinases (MMPs) 9
and 12 [6–8], and cathepsins S and K [9, 10]. Protease-
activatable NIRF probes, so-called smart optical probes, are
now available (Perkin Elmer; Waltham, MA, USA) for
preclinical research applications. Protease-sensing optical
probes are autoquench fluorescent probes that convert from
a nonfluorescent state to a fluorescent state by proteolytic
activation of lysosomal cysteine or serine proteases like
cathepsins. By inserting enzyme-specific peptide stalks
between the carrier and the fluorochromes the utility of
these probes has been extended to other enzymes such as
MMPs. The availability of protease-activatable probes may
lead to the eventual development of such optical imaging
agents as probes for use in the clinic.
Imaging Modalities for Measuring Inflammation
in Aortic Aneurysms
Risk of rupture is an important parameter to consider in
terms of management of aortic aneurysms, therefore
diagnostic testing is the first step in establishing a treatment
strategy. The most promising of these tests involve the use
of classical imaging to detect morphological and metabolic
changes that would identify patients with an increased risk
for disease progression. Imaging modalities such as
ultrasonography (US), contrast-enhanced CT angiography
(CTA), and MRI are able to provide anatomical informa-
tion. Aortic aneurysms provide an attractive target for
molecular imaging because of their relatively large size as
compared with atherosclerotic lesions. The addition of extra
information regarding pathophysiology and molecular
events would certainly provide an earlier time point
prognosis of aneurysm instability, which in turn will lead
to better management of the disease. Molecular and
functional imaging will lead the charge toward better
biomarkers and for more target-specific probes. Moreover,
imaging of aortic aneurysms will be improved by combin-
ing an anatomical reference together with PET or optical
imaging [11, 12•]. The use of target-specific contrast agents
and/or nanoparticles [13•] will also serve to deliver, initially
in animal models, better prognosis of aneurysms.
Imaging Anatomical Features
Ultrasonography is a cost-effective, highly sensitive and
specific imaging technique, which is the method of choice
for the detection and follow-up of aortic aneurysms. The
technique is used to determine the size of the aneurysm and
to predict its expansion. Three-dimensional (3D) ultraso-
nography has also been employed to improve spatial
definition. However, the technique cannot account for the
individual variability in the expansion of aneurysms. A
promising development has been the use of targeted agents
directed against important pathological processes in the
aneurysm wall during inflammation. Anti–P-selectin anti-
bodies bound to perfluorocarbon-filled microbubbles have
been developed to target P-selectin in activated platelets
[14, 15]. P-selectin plays an essential role in the initial
recruitment of leukocytes (white blood cells) to the site of
injury during inflammation.
CTA is primarily used for preparatory work before
endovascular surgery. A number of anatomical parameters
are derived to give informed treatment decisions by
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determining the feasibility of endovascular repair. Beyond
this, CTA does have the disadvantage of requiring ionizing
radiation and the administration of iodinated contrast
agents.
In contrast, MRI uses non-ionizing radiation and can
acquire images with high-resolution 3D anatomical features
(sub-millimeter), good temporal resolution, and excellent
soft tissue contrast. Magnetic resonance angiography
(MRA) can be obtained either with fast gradient echo
sequences after an injection of gadolinium, or with time-of-
flight sequences that do not require an injection but have a
longer acquisition time. Moreover, MRI can provide an
insight into the degree of inflammation by measuring the
presence of endogenous iron in macrophages and neutro-
phils that contain hemosiderin [16•].
Molecular Imaging
PET/SPECT/CT Imaging
An imaging modality that offers a better understanding
of the pathophysiology of aneurysms is PET. Several
reports have highlighted the potential role of fluorine
18-fluorodeoxyglucose (FDG) for the assessment of
various aortic diseases based on FDG accumulation. In
patients, a strong correlation was found between
increased FDG uptake and the progression of aneurysm
size, emphasizing that FDG-PET is clinically feasible
and available [17]. Furthermore, the stage of plaque
development and the level of glucose metabolism within
atherosclerotic plaques [18] can be correlated. Accumula-
tion of active macrophages has also been shown to
increase the uptake of tracer [19]. However, FDG-PET
alone is limited by the low spatial resolution and a lack of
morphological information. One way in which this can be
overcome is through the use of dual-modality PET/CT,
which has emerged as a new diagnostic technique for
vascular applications [11].
The implementation of PET/CT has also embraced the
use of nanoparticles [20•] on these systems. Their utiliza-
tion when targeted to macrophages in the form of
nanoparticle-based PET reporters has recently been
reported. The abundance and pivotal role of macrophages
in aneurysm formation [3, 21, 22] makes them an
interesting and clinically relevant imaging target. PET-CT
imaging was performed in a mouse model of aortic
aneurysm using 18F-cross-linked iron oxide (CLIO) nano-
particles which showed that trace concentrations were
detectable [23•]. Thus, PET-CT imaging with 18F-CLIO
nanoparticles allows quantitation of macrophage content.
MMPs play a major role in the growth of aortic
aneurysms and of their subsequent rupture. Razavian
et al. [24•] demonstrated in an animal model that
radiotracers with specificity for activated MMPs could
be used to detect and quantify MMP activation by
microSPECT/CT.
Molecular MRI
Molecular MRI now offers the ability to image cellular and
subcellular level events. Targeted MRI contrast agents have
been developed to enable imaging of low levels of
expressed targets in vivo. Furthermore, nanoparticles that
act as novel contrast agents have been reported that can be
potentially developed for diagnostic purposes. Other spe-
cialized MRI probes have been developed to image enzyme
activity in vivo. These and other advances in molecular
MRI offer great promise for the future and have significant
potential for clinical translation.
MRI contrast agents based upon ultra small, super-
paramagnetic iron oxide (USPIO) particles have recently
been used [25•] to demonstrate imaging of the inflamma-
tory process involved in aortic aneurysms. USPIO particles
are known to accumulate in macrophages in atherosclerotic
lesions. A method to assess USPIO uptake within the site of
the aneurysm in patients was performed by measurement of
semi-quantitative T2 and T2* relaxation times. Although
this study involved only a limited number of patients, it
demonstrated the potential of molecular MRI to evaluate
biological processes involved with inflammation of the
aortic wall and highlights the fact that USPIO contrast
agents are clinically available.
It was recently demonstrated in an animal model that
inflammation associated with aneurysms could be evaluated
noninvasively with MRI and the use of activatable contrast
agents. Myeloperoxidase (MPO) is an enzyme found in
neutrophils and macrophages and has the potential to be an
interesting biomarker for detecting aneurysms. DeLeo et al.
[26] evaluated the use of an MPO-sensing activatable MRI
contrast agent as a biomarker of the inflammatory neutro-
phils and macrophages present in a carotid artery brain
aneurysm animal model. They were able to visualize
aneurysmal inflammation in the brain using clinical
strength MRI. A paramagnetic MPO substrate, di-5-
hydroxytryptamide of gadopentetate dimeglumine, was
used to specifically enhance the MRI signal. We are not
aware of any similar work relating to molecular imaging of
MPO activity in vivo for aortic aneurysms, however, the
activation of macrophages or neutrophils where myeloper-
oxidase is secreted has been reported [27, 28].
A recently developed [29, 30] MRI contrast agent, P947,
to target MMPs in vivo was evaluated by Bazeli et al. [31].
They showed that MRI using P947 allows detection of
MMP activity within the inflammatory wall of experimental
abdominal aortic aneurysms.
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Optical Imaging
Optical molecular imaging is a recently introduced tech-
nique that can monitor molecular processes in vivo. From
its potential in preclinical studies, it has already shown
promise as a tool that will complement classical (nuclear)
diagnostic imaging where anatomical references can be
superimposed upon molecular events in the format of a
multimodality imaging platform. Recently, tumor-specific
intraoperative fluorescence imaging has been reported for
ovarian cancer in patients [32••].
The preclinical optical probes most extensively tested in
cardiovascular animal models have been on MMP activity.
MMP activity has been shown in animal models [12•, 33•]
using an MMP-activatable probe, MMPSense (Perkin
Elmer; Waltham, MA, USA). Moreover, Kaijzel et al.
[12•] showed that increased MMP activity could already be
detected in fibulin-4 (FBLN4) heterozygous mice even
before the aneurysm had actually formed (Fig. 1). 3D co-
registration of the optical image with CT pinpointed the
MMP activity to the aortic arch (Fig. 2). Fluorescent
lifetime of the probe also correlated with and confirmed
the location and specificity of MMP activity.
Cathepsin activity has also been documented with
respect to cardiovascular disorders [34•]. Chen et al. [35]
demonstrated in vivo that cathepsin B, and potentially other
proteases, may serve as a biomarker for vulnerable plaques
in an animal model. More recently, direct in vivo evidence
from studies on mice showed that cathepsin S–induced
elastolysis accelerates arterial and aortic valve calcification
in chronic renal disease [36]. This non-targeted enzyme-
activatable approach has revealed various new findings.
However, the identification of new biomarkers of inflam-
mation with target-specificity will be more sought after in
the future for early detection of aortic aneurysms. Vascular
endothelial growth factor receptor (VEGFR) expression
was found to increase in aortic aneurysm mouse models in
a diameter-dependent fashion [37•] during in situ NIRF
imaging. This may open the door toward clinical VEGFR
expression whole body imaging strategies, which could
improve real-time monitoring of aneurysmal disease.
Multimodality Imaging Using Nanoparticles
Polymer-coated iron oxide nanoparticles can be used as
imaging contrast agents whereby different imaging moieties
can be conjugated for use in a number of modality settings.
Two of the nanoparticles, Feraheme and aminoSPARK, are
commercially available but have been chemically modified
to achieve a specific function. The aminoSPARK nano-
particles are conjugated to near-infrared fluorescent (NIRF)
tags giving the structure both optical and MRI properties.
PET isotopes can also be conjugated onto the nanoparticles.
Furthermore, the use of iron oxide particles also has
applications as MRI contrast agents as the core can also
have a structure that makes it superparamagnetic, thus
making it compatible for MRI studies.
Human ferritin nanoparticles (HFn) conjugated to an
Arg–Gly–Asp (RGD) peptide were recently described in
mouse carotid and abdominal aortic aneurysm models
Fig. 1 Three-dimensional registration of MMP upregulation using
MMPsense 680 in live fibulin-4 animals using fluorescence molecular
tomography imaging. A gradual increase in fluorescence, and thus
MMP activation, is already seen in the heterozygous pre-aneurysmal
aortic lesions of the fibulin-4+/R mice (b) compared to wild-type
fibulin-4+/+ animals (a). Homozygous aneurysmal fibulin-4R/R mice
with a 2–3 fold dilated thoracic aortic arch (c) show a much higher
fluorescence level [12•]. (Images provided by R. Ridwan)
14 Curr Cardiovasc Imaging Rep (2012) 5:11–18
[13•]. The RGD-HFn structure and HFn alone were both
chemically modified to accommodate a NIRF label for in
vivo imaging. It was found that RGD-HFn showed
significantly higher signal than HFn alone in the aortic
aneurysm models and also when compared to non-diseased
regions. Histology showed that RGD-HFn co-localized
with macrophages in aortic aneurysm lesions. The target
specificity of the RGD-HFn structure will allow more
comprehensive detection of aneurysmal vascular disease.
The use of cross-linked iron oxide nanoparticles for
PET-CT imaging with 18F-CLIO demonstrated quantitation
of macrophage content in a mouse aortic aneurysm model
[23•]. This dual-modality approach enabled a reduction in
the nanoparticle dose to clinical levels (4.5 mg of iron
oxide/kg body weight, which is lower than the recommen-
ded clinical dose for Feraheme). This would have the
beneficial effect of being less toxic if the approach
translates toward the clinic. The same laboratory also
showed that fusion of radionuclide-based molecular (PET)
and structural CT modalities could be integrated with
fluorescence molecular tomography (FMT). The trio of
modalities was integrated and visualized together through a
nanoparticle common platform [38•].
Conclusions and Future Perspectives
Nowadays, aneurysms can be identified with US or CT and
can be treated by open or endovascular surgery once they
have formed. However, the combination of their small size,
unpredictability of rupture, and non-linear expansion means
that anatomical imaging alone is insufficient. Indeed, the
mortality rate continues to rise and the disease is often
under-diagnosed in cases where sudden death occurs. In
particular, these new tools, as also addressed by the Food
and Drug Administration Critical Path Initiative, are needed
to increase the speed, efficiency, and cost-effectiveness of
early diagnosis and for drug development. The unmet needs
are very apparent when one considers that methylene blue
and indocyanine green (ICG) are the only fluorescent-based
imaging probes that are FDA-approved. ICG was approved
in the late 1950s. The clinical recommendations for the
monitoring of molecular events in patients with aortic
aneurysms were made in 2005 [39]. It mentions molecular
MRI, FDG-PET, and gives a future perspective to the
use of nanoparticles. Optical imaging is absent from this
list as it is a recently introduced technique and remains
still limited for use in preclinical models. However, it is
clear that the future clinical interest for treatment and
monitoring of aortic aneurysms would be of imaging
molecular markers using target-specific approaches in
combination with anatomical imaging. The promise of
target-specific optical markers was recently given prom-
inence in a clinical study of patients with advanced-
stage ovarian cancer [32••]. These data were the first to
demonstrate the success of using intraoperative tumor-
specific fluorescence imaging. This study also has rele-
vance for other diseases as the early detection means
Fig. 2 Complementary anatomical (CT) and optical molecular
imaging of pre-aneurysmal lesions in aneurysmal fibulin-4 mice. a
Near-infrared fluorescence images of MMPSense 680 in vivo at 20
hours after injection of a FBLN4 knockdown mouse projected onto
the mouse image. b 3D fluorescence-mediated tomography (FMT) and
CT co-registration. To reliably identify the region of interest, FMT
imaging was hybridized with CT imaging for anatomic reference.
Within both datasets, fiducial points were tagged to define their X-Y-Z
coordinates. Using these coordinates, FMT and CT data are fused.
While the aorta of the FBLN4 knockdown mouse does not show
anatomical signs of aneurysm formation (indicated with the yellow
arrow), optical molecular imaging already indicated increased
protease activity in the aortic arch compared to normal animals
[12•]. (FMT-CT coregistration image provided by J. Dijkstra)
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improved prognosis and more options for therapeutic and
intraoperative intervention.
MMP and cathepsin activity have been monitored in
animal studies using activatable probes but these are not
specific for any particular target. Two recent publications
have provided evidence of potential molecular imaging–
targeted approaches for aortic aneurysm disease. VEGFR
expression was shown to be concordant with aortic
aneurysm growth [37•] during NIRF in vivo imaging in
mice. A genetically engineered human protein cage
conjugated to a RGD peptide demonstrated imaging of
vascular inflammation [13•]. The latter also opens the door
for nanoparticle and multimodality imaging. Anatomical
imaging can provide co-localization of morphology with
molecular function of aneurysmal events. The development
of radiotracers with novel contrast properties for MRI, CT,
or US will enhance the multimodality element to provide
for new insights into the pathophysiology of aortic
aneurysms. Iron oxide particles will also most likely be at
the forefront of a move toward novel nanoparticle technol-
ogies. Feraheme is a carbohydrate-coated iron-oxide nano-
particle that was recently approved by the FDA in the
US for the treatment of iron deficiency anemia in adult
patients with chronic kidney disease. A number of
groups are riding on the back of this approval by
exploring Feraheme analogous, particles that are opti-
mized to target macrophages to enable eventual fast-
track into clinic [23•, 40]. Nahrendorf et al. [38•] took a
PET/CT/optical approach incorporating the clinical PET
tracer 18F and a fluorochrome for optical studies. Sadat et
al. [25•] used USPIO contrast agents that have proved so
effective for MRI in animal models to demonstrate that
clinical aortic wall inflammation using USPIO-enhanced
MRI is feasible.
The potential clinical impact lies in the fact that several
molecular changes can already be monitored in vivo before
the aneurysm has actually formed. Implementation of these
novel molecular imaging techniques in humans will provide
a diagnostic tool to predict aneurysm formation in patients
[41•]. An example is the fluorescence molecular tomo-
graphic imaging of elevated protease activity in vivo in
FBLN4 knockdown mice in which increased MMP activity
could already be monitored with near-infrared fluorescence
probes before the aneurysm had actually formed [12•]. At
present, these FMT systems are only suited for experimen-
tal research on relatively small animal models. However,
intravascular near-IR fluorescence catheters are promising
tools for diagnostic imaging of protease activity in the
vascular system [42, 43] since these catheters are applicable
to humans and do not require large imaging equipment. In
addition to conventional imaging modalities, these new
diagnostic tools that interrogate the aneurysmatic lesion
could potentially serve to test pathophysiological hypothe-
ses to identify the risk while the disease remains undetected
and to evaluate novel therapeutic strategies. Future work
will answer whether these imaging approaches can further
improve our ability to diagnose the disease, assess
treatment efficacy, and allow clinical translatability.
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